Clinical Trials Logo

Clinical Trial Summary

The primary objectives of this study are: Phase 1: To evaluate the safety of sequenced therapy with lenzilumab and axicabtagene ciloleucel in participants with relapsed or refractory large B-cell lymphoma and identify the most appropriate dose of lenzilumab for Phase 2. Phase 2: To evaluate the incidence of neurologic events with sequenced therapy given at the recommended Phase 2 dose (RP2D) of lenzilumab in participants with relapsed or refractory large B-cell lymphoma.


Clinical Trial Description

This study was intended to be a Phase 1/2, but the planned Phase 2 part has been canceled. All participants who received an infusion of lenzilumab and axicabtagene ciloleucel will be provided the opportunity to transition to a separate long-term follow-up (LTFU) study, KT-US-982-5968. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04314843
Study type Interventional
Source Gilead Sciences
Contact
Status Terminated
Phase Phase 1
Start date May 26, 2020
Completion date July 27, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06079164 - Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma Phase 1
Terminated NCT03704298 - Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma Phase 1
Not yet recruiting NCT06414148 - MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma Phase 2
Recruiting NCT05800977 - A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma Phase 1/Phase 2